SecBot SecBot

RNAC

Cartesian Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001453687 Biotech & Drug Discovery
$6.08 −0.10 (−1.62%)
Oct 26 4:00 PM ET · prev $6.18
Market cap
$193.9M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$38.50
+533% · range $16.00–44.00
Next earnings
Nov 4
in 9 days · EPS est. −$1.01
1 year
−31.3%
from $8.85 · Oct 27
30 days
−15.7%
from $7.21
52-week range
$5.84–10.59
−43% from high · low Jun 5
Avg volume 20D
144.8K
shares / day
Short interest
1.86M
≈6.1% of shares · +2.9%
Days to cover
12.6
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 4, 2026
Strongest BULLISH Cartesian Therapeutics announced additional positive retreatment data for its lead CAR-T candidate…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 23 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.560 → −$1.010 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +2.9% to 1.86M shares. 12.6 days to cover, ≈6.1% of shares.

  • TrendDOWNTREND

    24% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD819,239$8.5M
VANGUARD CAPITAL MANAGEMENT LLCADD555,823$5.8M
FMR LLCTRIM368,429$3.8M
GEODE CAPITAL MANAGEMENT, LLCADD356,525$3.7M
UBS Group AGADD208,647$2.2M
VANGUARD FIDUCIARY TRUST COADD91,854$957.1K
VANGUARD PORTFOLIO MANAGEMENT LLCADD87,317$909.8K
GOLDMAN SACHS GROUP INCDOUBLED80,572$839.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +533%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 30, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 29, 2026Needham
REITERATE
REITERATEBuy
Aug 18, 2026Wedbush
REITERATE
REITERATEOutperform
Jun 10, 2026Wedbush
REITERATE
REITERATEOutperform
Jun 9, 2026Needham
REITERATE
REITERATEBuy
Jun 9, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Apr 2, 2026
Kalayoglu Murat
10%+ Owner
EXERCISE758,001 sh
Apr 2, 2026
Hoge Elizabeth
10%+ Owner
EXERCISE22,740.03 sh
Apr 2, 2026
Hoge Elizabeth
10%+ Owner
EXERCISE758,001 sh
Apr 2, 2026
Kalayoglu Murat
10%+ Owner
EXERCISE22,740.03 sh
Mar 13, 2026
Singer Michael
Director
GIFT6,555 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
−$1.01
EPS estimate, this quarter
−80%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.01-$1.01–-$1.01-46.4%$121.4K
Next Q-$1.03-$1.03–-$1.03-47.1%$235.7K
Current FY-$2.78-$2.78–-$2.78+17.0%$419.1K
Next FY-$3.81-$3.81–-$3.81-42.2%$285.7K

Short side

FINRA· Sep 30, 2026
1,855,626
shares short
+2.9%
vs prior settlement
12.6
days to cover
≈6.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 Clinical trial readout
T-90d Trial Readout: Decartes-08 (Phase 3)
Trial: Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to T
Sep 29, 2026 SEC
Cartesian Therapeutics announced additional positive retreatment data for its lead CAR-T candidate, Descartes-08, in…
8-K — Impact 6/10
Aug 6, 2026 SEC
Cartesian Therapeutics reported Q2 2026 GAAP net income of $15.8M ($0.47 basic EPS), compared to net income of $15.9M…
8-K — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
819,239 shares ($8.5M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
555,823 shares ($5.8M)
May 26, 2026 SEC
Cartesian Therapeutics secured a senior secured credit facility from K2 HealthVentures for up to $150 million, with an…
8-K — Impact 7/10
May 26, 2026 Press
Cartesian Therapeutics secured a $150M non-dilutive credit facility from K2 HealthVentures, with an initial $50M…
Impact 7/10
Apr 2, 2026 Insider
Kalayoglu Murat acquired via exercise 758,001 shares
10%+ Owner
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
RNAC Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Oct 6, 2026
Trial readout
T-90d Trial Readout: Decartes-08 (Phase 3)
Trial: Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis Sponsor: Cartesian…
Oct 2, 2026
Press release
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology…
Sep 30, 2026
Trial readout
T-90d Trial Readout: Decartes-08 (Phase 3)
Trial: Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis Sponsor: Cartesian…
Sep 6, 2026
Trial readout
T-90d Trial Readout: Descartes-08 (Phase 2)
Trial: Descartes-08 for Patients With Systemic Lupus Erythematosus Sponsor: Cartesian Therapeutics Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING…
Sep 3, 2026
Press release
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology…

SecBot reports

3 filings · 1 press release · 2 bullish · 0 bearish · 1 neutral
All RNAC filing & press-release reports (4)